Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory / Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey


Beksac M., Seval G. C. , PAYDAŞ S., Tuglular T. F. , Arslan O., GÖKER H., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.19, 2019 (SCI İndekslerine Giren Dergi)

Atıf İçin Kopyala
  • Cilt numarası: 19 Konu: 10
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.clml.2019.09.402
  • Dergi Adı: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA